普利製藥(300630.SZ):比拉斯汀口崩片獲得臨牀試驗批件
格隆匯5月22日丨普利製藥(300630.SZ)公吿,公司子公司浙江普利藥業有限公司(以下簡稱"浙江普利")於近日收到了國家藥品監督管理局(以下簡稱"NMPA")簽發的藥物臨牀試驗批准通知書,藥品名稱為比拉斯汀口崩片。
比拉斯汀是一種新型的第二代 H1抗組胺藥,非鎮靜、長效組胺拮抗劑,具有選擇性外周H1受體拮抗劑親和力,對毒蕈鹼受體無親和力,無心臟毒性,口服給藥吸收迅速,具有良好的耐受性、安全性和較高的生物利用度。且對於腎臟功能不全、肝臟功能不全患者無需調整用量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.